“PRINCIPLES OF CLINICAL PHARMACOLOGY” COURSE

2015-2016 SCHEDULE

All sessions will meet Thursday evenings from 6:30 p.m. to approximately 7:45 p.m.
in the NIH Clinical Center, Building 10, in the Lipsett Amphitheater in Bethesda, Maryland.
Course Web Site: http://pcp.nihtraining.com

MODULE 1: PHARMACOKINETICS:

- September 3rd: Introduction to Clinical Pharmacology and Pharmacokinetics
  (Clinical Applications of Pharmacokinetics)
  J. Lertora (NIH-CC)

- September 10th: Compartmental analysis of drug distribution
  J. Lertora (NIH-CC)

- September 17th: Chemical assay of drugs and drug metabolites
  S. Markey (NIST)

- September 24th: Use of positron emission tomography (PET) in pharmacokinetics
  R. Innis (NIH-NIMH)

- October 1st: Drug absorption and bioavailability
  J. Lertora (NIH-CC)

- October 8th: Effects of renal disease on pharmacokinetics
  J. Lertora (NIH-CC)

- October 15th: SPECIAL LECTURE: Pharmacokinetics in patients requiring renal replacement therapy
  A. Atkinson (Northwestern Univ.) and G. Susla (MedImmune, Inc)

- October 22nd: Noncompartmental vs. compartmental approaches to PK analysis
  P. Vicini (MedImmune, Inc)

- October 29th: Effects of liver disease on pharmacokinetics
  J. Lertora (NIH-CC)

- November 5th: Population pharmacokinetics
  R. Miller (Daiichi Sankyo, Inc.)

MODULE 2: DRUG METABOLISM AND TRANSPORT:

- November 12th: Pathways of drug metabolism
  S. Markey (NIST)

- November 19th: Biochemical mechanisms for drug toxicity
  A. Beasley Green (NIST)

- December 3rd: Pharmacogenomics
  D. Flockhart (IUPUI)

- December 10th: Drug Interactions
  S. Robertson (Vertex Pharmaceuticals Inc)

- December 17th: Equilibrative and concentrative drug transport
  J. Ware (Genentech, Inc.)

- January 7th: SPECIAL LECTURE: P-glycoprotein and drug transport
  M. Gottesman (NIH-OIR) and M. Hall (NIH-NCI)

MODULE 3: ASSESSMENT OF DRUG EFFECTS:

- January 14th: Dose response and concentration response analysis
  J. Lertora (NIH-CC)

- January 21st: Physiological and laboratory markers of drug effect
  J. Woodcock (FDA-CDER)

- January 28th: Disease progression models and clinical trial simulation
  D. Mould (Projections Research, Inc.)

MODULE 4: OPTIMIZING AND EVALUATING PATIENT THERAPY:

- February 4th: Clinical analysis of adverse drug reactions
  C. Chamberlain (FDA-CDER)

- February 11th: Developmental and pediatric pharmacology
  J. van den Anker (Children’s National Medical Center)

- February 18th: Drug therapy in pregnant and nursing women
  C. Stika (Northwestern Univ.)

- February 25th: Drug therapy in the elderly
  D. Abernethy (FDA-CDER)

- March 3rd: Quality assessment of drug therapy
  C. Daniels (UCSD)

MODULE 5: DRUG DISCOVERY AND DEVELOPMENT:

- March 10th: Drug discovery
  E. Sausville (Univ. of Maryland Medical System)

- March 17th: Nonclinical drug development
  C. Takimoto (Centocor R&D, Inc./Johnson & Johnson)

- March 24th: Animal scale up and Phase I studies
  J. Collins (NIH-NCI)

- March 31st: Development and applications of cell based therapies
  D. Stroncek (NIH-CC)

- April 7th: Development of biotechnology products and large molecules
  P. Garzone ((Pfizer, Inc.)

- April 14th: Design of clinical drug development programs
  C. Breder (FDA-CDER)

- April 21nd: Role of the FDA in guiding drug development
  C. Peck (CDDS, UCSF)